1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Mar 2024
Admin
News Article

Lupin Gets Marketing Approval for Generic Vibramycin Injection

Lupin gets US FDA marketing approval for generic Vibramycin for injection

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for doxycycline for injection USP, 100 mg/vial (single-dose vial), to market a generic equivalent of Vibramycin for injection, 100 mg/vial, of Pfizer Inc. The product will be manufactured at Lupin’s Nagpur facility in India.

Doxycycline Indication

Doxycycline for injection USP is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs.
Doxycycline for injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Annual Sale

Doxycycline for injection USP (RLD Vibramycin) had estimated annual sales of USD 47 million in the US (IQVIA MAT January 2024).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.